PNCA
MCID: PNC035
MIFTS: 86

Pancreatic Cancer (PNCA)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Pancreatic Cancer

MalaCards integrated aliases for Pancreatic Cancer:

Name: Pancreatic Cancer 57 12 75 53 74 37 13 55 43 15 38
Pancreatic Carcinoma 57 12 53 74 55 44 15 17 72
Pancreatic Carcinoma, Familial 12 75 72
Familial Pancreatic Carcinoma 53 59 29
Carcinoma of Pancreas 12 29 6
Pancreatic Neoplasm 12 17 72
Malignant Neoplasm of Pancreas 72 33
Pancreatic Acinar Carcinoma 57 74
Familial Pancreatic Cancer 53 59
Cancer of the Pancreas 53 6
Pancreatic Neoplasms 6 44
Pancreatic Tumor 12 55
Malignant Neoplasm of Body of Pancreas 12
Malignant Neoplasm of Head of Pancreas 12
Malignant Neoplasm of Tail of Pancreas 12
Pancreatic Cancer, Susceptibility to 6
Hereditary Pancreatic Carcinoma 53
Pancreatic Carcinoma, Somatic 57
Carcinoma of Head of Pancreas 6
Hereditary Pancreatic Cancer 53
Exocrine Pancreas Carcinoma 12
Pancreatic Cancer, Somatic 57
Neoplasm of the Pancreas 29
Ca Body of Pancreas 12
Ca Head of Pancreas 12
Ca Tail of Pancreas 12
Pancreas Carcinoma 53
Cancer, Pancreatic 40
Pancreas Neoplasm 12
Pancreatic Tumors 15
Exocrine Cancer 12
Pancreas Cancer 53
Pnca 74

Characteristics:

Orphanet epidemiological data:

59
familial pancreatic carcinoma
Inheritance: Multigenic/multifactorial; Age of onset: Adult;

OMIM:

57
Inheritance:
somatic mutation
autosomal dominant
multifactorial

Miscellaneous:
may be seen with other forms of cancer in a family


HPO:

32
pancreatic cancer:
Inheritance autosomal dominant inheritance somatic mutation


Classifications:



External Ids:

Disease Ontology 12 DOID:1793 DOID:4905
OMIM 57 260350
KEGG 37 H00019
NCIt 50 C3305 C3850
MESH via Orphanet 45 C535837
ICD10 via Orphanet 34 C25
UMLS via Orphanet 73 C2931038
Orphanet 59 ORPHA1333
MedGen 42 C0235974
UMLS 72 C0030297 C0153458 C0153459 more

Summaries for Pancreatic Cancer

NIH Rare Diseases : 53 Familial pancreatic cancer (FPC) is the occurrence of pancreatic cancer in two or more first-degree relatives (parent and child, or two siblings). It is sometimes referred to as FPC only when there is not a known hereditary cancer syndrome in an affected family. In familial cases, pancreatic cancer often occurs before age 50 (earlier than other forms of pancreatic cancer). In 60% of cases it occurs within the head of the pancreas. Symptoms of pancreatic cancer are generally non-specific and may include pain in the upper abdomen that radiates to the back; loss of appetite; significant weight loss; and jaundice due to bile duct obstruction. Pancreatic cancer often goes undetected until the advanced stages of the disease, and rapid tumor growth and metastasis are common. A specific genetic cause of FPC (in the absence of a known syndrome) has not been identified. Familial cases of pancreatic cancer due to hereditary conditions may be caused by mutations in any of several genes. Individuals who carry a mutation in one of these genes are often at an increased risk of other types of cancers as well. Currently, only 10-20% of families with FPC will have a mutation identified by genetic testing. Hereditary cancer syndromes and other inherited conditions associated with pancreatic cancer include: BRCA1 hereditary breast and ovarian cancer syndrome BRCA2 hereditary breast and ovarian cancer syndrome Peutz-Jeghers syndrome FAMMM syndrome Lynch syndrome Hereditary pancreatitis In many cases, inheritance of FPC is autosomal dominant; in some cases, is may be multifactorial. It is important to note that pancreatic cancer itself is not inherited, but a genetic predisposition to developing cancer is inherited. Treatment may include surgical resection, chemotherapy, and/or radiotherapy. Resection is the only potential cure, but most patients have advanced, non-resectable tumors by the time of diagnosis.

MalaCards based summary : Pancreatic Cancer, also known as pancreatic carcinoma, is related to hereditary breast ovarian cancer syndrome and pancreatic ductal adenocarcinoma, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Pancreatic Cancer is SMAD4 (SMAD Family Member 4), and among its related pathways/superpathways are Pancreatic cancer and Gastric cancer. The drugs Dalteparin and Thrombin have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, pancreas and liver, and related phenotypes are pancreatic adenocarcinoma and abdominal pain

Disease Ontology : 12 An endocrine gland cancer located in the pancreas.

OMIM : 57 Pancreatic cancer shows among the highest mortality rates of any cancer, with a 5-year relative survival rate of less than 5%. By the time of initial diagnosis, metastatic disease is commonly present. Established risk factors include a family history of pancreatic cancer, a medical history of diabetes type 2, and cigarette smoking (summary by Amundadottir et al., 2009). (260350)

MedlinePlus : 43 The pancreas is a gland behind your stomach and in front of your spine. It produces the juices that help break down food and the hormones that help control blood sugar levels. Pancreatic cancer usually begins in the cells that produce the juices. Some risk factors for developing pancreatic cancer include Smoking Long-term diabetes Chronic pancreatitis Certain hereditary disorders Pancreatic cancer is hard to catch early. It doesn't cause symptoms right away. When you do get symptoms, they are often vague or you may not notice them. They include yellowing of the skin and eyes, pain in the abdomen and back, weight loss and fatigue. Also, because the pancreas is hidden behind other organs, health care providers cannot see or feel the tumors during routine exams. Doctors use a physical exam, blood tests, imaging tests, and a biopsy to diagnose it. Because it is often found late and it spreads quickly, pancreatic cancer can be hard to treat. Possible treatments include surgery, radiation, chemotherapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

KEGG : 37
Infiltrating ductal adenocarcinoma is the most common malignancy of the pancreas. When most investigators use the term 'pancreatic cancer' they are referring to pancreatic ductal adenocarcinoma (PDA). Normal duct epithelium progresses to infiltrating cancer through a series of histologically defined precursors (PanINs). The overexpression of HER-2/neu and activating point mutations in the K-ras gene occur early, inactivation of the p16 gene at an intermediate stage, and the inactivation of p53, SMAD4, and BRCA2 occur relatively late. Activated K-ras engages multiple effector pathways. Although EGF receptors are conventionally regarded as upstream activators of RAS proteins, they can also act as RAS signal transducers via RAS-induced autocrine activation of the EGFR family ligands. Moreover, PDA shows extensive genomic instability and aneuploidy. Telomere attrition and mutations in p53 and BRCA2 are likely to contribute to these phenotypes. Inactivation of the SMAD4 tumour suppressor gene leads to loss of the inhibitory influence of the transforming growth factor-beta signalling pathway.

UniProtKB/Swiss-Prot : 74 Pancreatic cancer: A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.

Wikipedia : 75 Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to... more...

Related Diseases for Pancreatic Cancer

Diseases in the Pancreatic Cancer family:

Pancreatic Cancer 1 Pancreatic Cancer 2
Pancreatic Cancer 3 Pancreatic Cancer 4

Diseases related to Pancreatic Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1038)
# Related Disease Score Top Affiliating Genes
1 hereditary breast ovarian cancer syndrome 34.3 TP53 PALB2 BRCA2 BRCA1
2 pancreatic ductal adenocarcinoma 33.8 MIR96 MIR221 MIR21 MIR155
3 adenocarcinoma 33.6 TP53 STK11 SMAD4 KRAS
4 colorectal cancer 33.1 TP53 STK11 SMAD4 MIR96 MIR34C MIR34B
5 pancreas disease 33.0 TP53 SMAD4 KRAS
6 breast cancer 32.9 TP53 STK11 SMAD4 PALB2 MIR96 MIR34A
7 hepatocellular carcinoma 32.8 TP53 SMAD4 MIR96 MIR34A MIR221 MIR21
8 peutz-jeghers syndrome 32.7 TP53 STK11 SMAD4 BRCA2
9 ovarian cancer 32.7 TP53 PALB2 MIR34C MIR34B MIR221 MIR21
10 lynch syndrome 32.7 TP53 KRAS BRCA2 BRCA1
11 cholangiocarcinoma 32.6 TP53 SMAD4 MIR21 KRAS
12 gastric cancer 32.6 TP53 SMAD4 MIR34A MIR221 MIR21 KRAS
13 prostate cancer 32.4 TP53 MIR96 MIR34A MIR221 MIR21 MIR15A
14 esophageal cancer 32.4 TP53 SMAD4 MIR34A MIR21 KRAS CDKN2B-AS1
15 lung cancer 32.4 TP53 STK11 MIR96 MIR34C MIR34B MIR34A
16 endocrine gland cancer 32.3 TP53 SMAD4 KRAS BRCA2 BRCA1
17 acinar cell carcinoma 32.3 TP53 SMAD4 BRCA2
18 melanoma 32.3 TP53 MIR96 MIR34C MIR34B MIR34A MIR221
19 bladder cancer 32.3 TP53 MIR221 MIR21 MIR10A KRAS CDKN2B-AS1
20 glioblastoma 32.2 TP53 MIR34A MIR221 MIR21 BRCA2
21 glioblastoma multiforme 32.1 TP53 MIR221 MIR21 MIR155
22 glioma 32.1 TP53 MIR34A MIR221 MIR21 MIR17 MIR15A
23 kidney cancer 32.0 TP53 MIR21 MIR17 MIR15A
24 familial adenomatous polyposis 31.9 TP53 SMAD4 KRAS
25 li-fraumeni syndrome 31.9 TP53 BRCA2 BRCA1
26 squamous cell carcinoma, head and neck 31.8 TP53 SMAD4 MIR221 MIR21 MIR15A MIR155
27 pancreatic neuroendocrine tumor 31.7 PALB2 BRCA2
28 bilateral breast cancer 31.7 PALB2 BRCA2 BRCA1
29 leukemia, acute myeloid 31.7 TP53 MIR34C MIR34B MIR221 MIR21 MIR155
30 dermatomyositis 31.6 MIR221 MIR21 MIR155
31 female breast cancer 31.6 TP53 PALB2 BRCA2 BRCA1
32 colloid carcinoma of the pancreas 31.6 SMAD4 KRAS BRCA2
33 gastrointestinal system cancer 31.5 TP53 SMAD4 KRAS
34 mutyh-associated polyposis 31.5 TP53 SMAD4 KRAS
35 diffuse large b-cell lymphoma 31.5 TP53 MIR221 MIR21 MIR155 MIR10A
36 cervical cancer 31.4 TP53 STK11 SMAD4 MIR21 CDKN2B-AS1
37 medulloblastoma 31.4 TP53 MIR34A MIR17 CDKN2B-AS1 BRCA2
38 ductal carcinoma in situ 31.4 TP53 BRCA2 BRCA1
39 coronary heart disease 1 31.3 MIR221 MIR17 MIR155 CDKN2B-AS1
40 oral squamous cell carcinoma 31.2 MIR96 MIR34C MIR34B MIR34A MIR221 MIR21
41 thyroid cancer, nonmedullary, 1 31.2 MIR34A MIR221 MIR15A MIR155
42 nasopharyngeal carcinoma 31.2 TP53 MIR34C MIR34B CDKN2B-AS1
43 intestinal disease 31.1 TP53 STK11 KRAS
44 polymyositis 31.1 MIR21 MIR155
45 leukemia, acute lymphoblastic 31.0 MIR221 MIR21 MIR155
46 breast adenocarcinoma 30.4 TP53 SMAD4 KRAS
47 melanoma-pancreatic cancer syndrome 12.7
48 pancreatic cancer 1 12.6
49 pancreatic cancer 4 12.6
50 pancreatic cancer 3 12.6

Comorbidity relations with Pancreatic Cancer via Phenotypic Disease Network (PDN): (show all 11)


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Cholangitis
Cholestasis Deficiency Anemia
Intestinal Obstruction Pancreatic Agenesis 1
Pancreatitis, Hereditary Protein-Energy Malnutrition
Somatostatinoma

Graphical network of the top 20 diseases related to Pancreatic Cancer:



Diseases related to Pancreatic Cancer

Symptoms & Phenotypes for Pancreatic Cancer

Human phenotypes related to Pancreatic Cancer:

59 32 (show all 26)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pancreatic adenocarcinoma 59 32 obligate (100%) Obligate (100%) HP:0006725
2 abdominal pain 59 32 hallmark (90%) Very frequent (99-80%) HP:0002027
3 weight loss 59 32 hallmark (90%) Very frequent (99-80%) HP:0001824
4 exocrine pancreatic insufficiency 59 32 hallmark (90%) Very frequent (99-80%) HP:0001738
5 back pain 59 32 hallmark (90%) Very frequent (99-80%) HP:0003418
6 anorexia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002039
7 chronic fatigue 59 32 hallmark (90%) Very frequent (99-80%) HP:0012432
8 poor appetite 59 32 hallmark (90%) Very frequent (99-80%) HP:0004396
9 jaundice 59 32 frequent (33%) Frequent (79-30%) HP:0000952
10 extrahepatic cholestasis 59 32 frequent (33%) Frequent (79-30%) HP:0012334
11 lymphadenopathy 59 32 frequent (33%) Frequent (79-30%) HP:0002716
12 functional intestinal obstruction 59 32 frequent (33%) Frequent (79-30%) HP:0005249
13 intestinal pseudo-obstruction 59 32 frequent (33%) Frequent (79-30%) HP:0004389
14 diabetes mellitus 59 32 occasional (7.5%) Occasional (29-5%) HP:0000819
15 nausea and vomiting 59 32 occasional (7.5%) Occasional (29-5%) HP:0002017
16 elevated hepatic transaminase 59 32 occasional (7.5%) Occasional (29-5%) HP:0002910
17 melanoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0002861
18 colon cancer 59 32 occasional (7.5%) Occasional (29-5%) HP:0003003
19 breast carcinoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0003002
20 hepatosplenomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0001433
21 neoplasm of the liver 59 32 occasional (7.5%) Occasional (29-5%) HP:0002896
22 intermittent diarrhea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002254
23 ovarian carcinoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0025318
24 peritoneal abscess 59 32 occasional (7.5%) Occasional (29-5%) HP:0100592
25 neoplasm of the pancreas 32 HP:0002894
26 increased level of l-fucose in urine 32 HP:0410067

Symptoms via clinical synopsis from OMIM:

57
Abdomen Pancreas:
pancreatic cancer
pancreatic ductal adenocarcinoma

Neoplasia:
pancreatic ductal adenocarcinoma

Clinical features from OMIM:

260350

UMLS symptoms related to Pancreatic Cancer:


nausea and vomiting, constipation, abdominal pain, pruritus, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Pancreatic Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.8 ACVR1B BRCA1 BRCA2 KRAS SMAD4 STK11
2 embryo MP:0005380 9.76 ACVR1B BRCA1 BRCA2 KRAS PALB2 SMAD4
3 integument MP:0010771 9.56 ACVR1B BRCA1 BRCA2 KRAS PALB2 SMAD4
4 neoplasm MP:0002006 9.17 BRCA1 BRCA2 KRAS PALB2 SMAD4 STK11

Drugs & Therapeutics for Pancreatic Cancer

Drugs for Pancreatic Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 710)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dalteparin Approved Phase 4 9005-49-6
2
Thrombin Approved, Investigational Phase 4
3
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
4
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
5
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
6
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
7
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
8
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
9
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
10
Etomidate Approved Phase 4 33125-97-2 36339 667484
11
Meperidine Approved Phase 4 57-42-1 4058
12
Glycolic acid Approved, Investigational Phase 4 79-14-1 757
13
Desflurane Approved Phase 4 57041-67-5 42113
14
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
15
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
16
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
17
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
18
Metronidazole Approved Phase 4 443-48-1 4173
19
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
20
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
21
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
22
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
23
Morphine Approved, Investigational Phase 4 57-27-2 5288826
24
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
25
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
26
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
27
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
28
Flurbiprofen Approved, Investigational Phase 4 5104-49-4 3394
29
Nimotuzumab Investigational Phase 4 780758-10-3, 828933-61-3
30 Flurbiprofen axetil Investigational Phase 4 91503-79-6
31 Parenteral Nutrition Solutions Phase 4
32 Fibrin Tissue Adhesive Phase 4
33 Fat Emulsions, Intravenous Phase 4
34 Soybean oil, phospholipid emulsion Phase 4
35 arginine Phase 4
36 Neurotransmitter Agents Phase 4
37 Adrenergic Agents Phase 4
38 Hemostatics Phase 4
39 Central Nervous System Stimulants Phase 4
40 Omega 3 Fatty Acid Phase 4
41 GABA Agents Phase 4
42 Nicotinic Agonists Phase 4
43 Cytochrome P-450 Enzyme Inhibitors Phase 4
44 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
45 Dopamine Agents Phase 4
46 Dopamine Uptake Inhibitors Phase 4
47 Hypnotics and Sedatives Phase 4
48 Dextrans Phase 4
49 Ferric Compounds Phase 4
50 Ulipristal acetate Phase 4 126784-99-4

Interventional clinical trials:

(show top 50) (show all 2636)
# Name Status NCT ID Phase Drugs
1 Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer. Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
2 Prospective Paired Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms Unknown status NCT01673334 Phase 4
3 The Effect of Application of Fibrinogen/Thrombin-coated Collagen Patch (TachoSil®) in Pancreaticojejunostomy for Prevention of Pancreatic Fistula After Pancreatoduodenectomy Unknown status NCT03269955 Phase 4 Fibrinogen/thrombin-coated collagen patch
4 Additional Effects of Perioperative Immunonutrition on Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
5 A Prospective, Randomized, Controlled, Multicenter Study of Kanglaite Injection for the Treatment of Cancer Cachexia Unknown status NCT02553187 Phase 4 Kanglaite Injection
6 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
7 Randomized Clinical Trial of Omega-3 Fatty Acid-supplemented Parenteral Nutrition Versus Standard Parenteral Nutrition in Patients Undergoing Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4 MCT/LCT and fish oil;MCT/LCT
8 Clinical Effectiveness of Serum Chromogranin A (CgA) Levels on Diagnostic Relevance, Response After Surgical Resection and Recurrence of Pancreatic Endocrine Tumors (PET) Unknown status NCT02759718 Phase 4
9 Randomized Controlled Trial Comparing Covered and Uncovered Biliary Self Expanding Metal Stents (SEMS) for Pre-operative Drainage During Neoadjuvant Therapy in Patients With Pancreatic Cancer Completed NCT02238847 Phase 4
10 A Prospective Study of Celiac Block Technique: One Injection or Two? Completed NCT00583479 Phase 4
11 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
12 Improved Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI) Completed NCT00920023 Phase 4 Superparamagnetic Iron Oxide Magnetic Resonance Imaging
13 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN) With Alcohol in Patients With Locally Advanced and Unresectable Pancreatic Adenocarcinoma: A Randomized Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
14 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
15 Prospective Randomized Trial Comparing Covered Metal Stents Placed Above and Across the Sphincter of Oddi in Malignant Biliary Obstruction: A Multi-nation, Multi-center Study Completed NCT01041612 Phase 4
16 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
17 RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction Completed NCT00980889 Phase 4
18 Randomized Clinical Trial of Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Undergoing Chemotherapy Treatment. Completed NCT00966277 Phase 4 Dalteparin
19 A Prospective Multi-center Randomized Study of the Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses Completed NCT02092519 Phase 4
20 Covered Versus Uncovered Metal Stents for Management of Distal Malignant Biliary Obstruction? Results of a Randomized Prospective Study. Completed NCT00280709 Phase 4
21 A SINGLE-ARM OPEN-LABEL INTERNATIONAL MULTI-CENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB MALATE (SU011248, SUTENT (REGISTERED)) IN PATIENTS WITH PROGRESSIVE ADVANCED METASTATIC WELL-DIFFERENTIATED UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMORS Completed NCT01525550 Phase 4 sunitinib
22 Pilot Study: Randomized Controlled Trial on the Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
23 Effects of Dexmedetomidine on Anaesthesia During IRE Procedures for Solid Tumours Completed NCT02044224 Phase 4 Dexmedetomidine
24 The Importance of Albumin Infusion Rate for Plasma Volume Expansion. AIR. A Phase III Assessor Blinded Parallel Group Randomized Study Completed NCT02728921 Phase 4 5% Albumin infusion 30 min;5% Albumin infusion 3 hours
25 Etomidate With Meperidine vs Midazolam With Meperidine for Sedation During Endodscopic Retrograde Cholangiopancreatogram (ERCP) Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
26 Standard and Immunostimulating Enteral Nutrition in Patients After Extended Gastrointestinal Surgery - A Prospective, Randomized, Controlled Clinical Trial Completed NCT00576940 Phase 4 Reconvan;Peptisorb
27 Title: The Impact of Immunostimulating Nutrition on Infectious Complications After Upper Gastrointestinal Surgery - A Prospective, Randomized, Clinical Trial. Completed NCT00558155 Phase 4 peptisorb;Stresson;Parenteral nutrition;Omegaven, Dipeptiven
28 Use of Polyethylene Glycolic Acid or Tachocomb to Prevent Pancreatic Fistula Following Distal Pancreatectomy: Prospective Multicenter Randomized Study Completed NCT01550406 Phase 4
29 Randomized Multi-Center Study Comparing No Drainage to Preoperative Biliary Drainage Using Metal Stents in Patients With Resectable Pancreatic or Periampullary Cancer Recruiting NCT01774019 Phase 4
30 Resectable Pancreatic Adenocarcinoma - Does the Type of Anesthesia Have an Impact on Circulating Tumor Cells? Recruiting NCT02335151 Phase 4 Desflurane
31 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Recruiting NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
32 A Multicenter Phase 4 Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients Recruiting NCT02812992 Phase 4 Nab-paclitaxel;Gemcitabine
33 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy for Periampullary Tumors: a Prospective, Randomized, Controlled Clinical Trial Recruiting NCT01642875 Phase 4
34 A Dose Escalation Safety Study of Locally-Delivered (Intra-Arterial) Gemcitabine in Unresectable Adenocarcinoma of the Pancreas Active, not recruiting NCT02237157 Phase 4 Gemcitabine, local delivery
35 HYPAR Trial - Hydrocortisone vs Pasireotide in Reducing Pancreatic Fistula and Other Complications After Pancreatic Resection - a Prospective, Randomized, Controlled Trial Active, not recruiting NCT02775227 Phase 4 Hydrocortisone;Pasireotide
36 H.O.P.E. Healing Optimization Through Preoperative Engagement: A Prospective Single Cohort Study to Evaluate the Effect of a Prehabilitation Program on Preoperative Outcomes in Upper GI Surgical Oncology Patients Enrolling by invitation NCT03642093 Phase 4
37 A Pilot Study of Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma Not yet recruiting NCT03891979 Phase 4 Antibiotics and Pembrolizumab
38 Creon (Pancrelipase) Therapy for Subjects With Exocrine Pancreatic Insufficiency (EPI) Due to Pancreatic Cancer: A Double-blind, Randomized, Parallel Design With 2 Dose Cohorts of Pancrelipase in Resected Pancreatic Cancer Subjects and an Open-label Single Dose Cohort in Non-resected Pancreatic Cancer Subjects Not yet recruiting NCT03859869 Phase 4 Pancrelipase;Placebo
39 Effect of Perioperative Epidural Block and Dexamethasone on Outcome of Patients Undergoing Pancreatic Cancer Surgery Not yet recruiting NCT04025840 Phase 4 Dexamethasone
40 A Randomized, Controlled, Double Blind, Multicenter Study of Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Advanced or Metastatic Pancreatic Cancer After First-line Treatment Not yet recruiting NCT02945267 Phase 4 Nimotuzumab plus S1;Placebo plus S1
41 Glycocalyx Levels in Patients Undergoing Pancreatectomy With Human Albumin 5% vs. Gelofusine Not yet recruiting NCT04058236 Phase 4
42 An Open Label Study to Evaluate the Effect of First Line Treatment With Tarceva in Combination With Gemcitabine on Overall Survival and Disease Progression in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer Terminated NCT00642733 Phase 4 erlotinib [Tarceva];gemcitabine
43 Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study Terminated NCT01768988 Phase 4 Placebo;Pregabalin
44 Quality of Life After Bilioenteric Anastomosis in Comparison to Endoscopically Placed Stents in Patients With Unresectable Pancreatic Cancer and Jaundice Terminated NCT01887041 Phase 4
45 Impact of Perioperative Dexamethasone and Flurbiprofen Axetil on Long-term Survival After Surgery for Non-small Cell Lung Cancer: A 2x2 Factorial Randomized Controlled Trial Terminated NCT03172988 Phase 4 Dexamethasone;Normal saline;Flurbiprofen axetil;Lipid microsphere
46 Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy Withdrawn NCT01401387 Phase 4
47 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Withdrawn NCT02570529 Phase 4 Albis®;Placebo
48 Pasireotide Treatment for Insulin Producing Pancreatic Neuro-endocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
49 CROSSFIRE Trial: Crossatlantic Randomized Controlled Trial Comparing Outcome in Survival After Systemic Plus Focal Therapy for Inoperable Pancreatic Carcinoma: Radiotherapy Versus Irreversible Electroporation Unknown status NCT02791503 Phase 2, Phase 3
50 A Phase III, Open-label, Randomized Study of the Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer Unknown status NCT02043288 Phase 3 NC-6004;Gemcitabine

Search NIH Clinical Center for Pancreatic Cancer

Inferred drug relations via UMLS 72 / NDF-RT 51 :


docetaxel
Fluorouracil
Fluorouracil
Ifosfamide
Ifosfamide
irinotecan
Irinotecan
Irinotecan hydrochloride
Octreotide
Octreotide Acetate
sunitinib
sunitinib malate
Tamoxifen
Tamoxifen Citrate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Pancreatic Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Pancreatic Cancer:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Pancreatic Cancer:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 21498393 22996367 19304471 22555974 15800326 23650429 21325070 8170938 12242449 24218514 23904171

Cochrane evidence based reviews: pancreatic neoplasms

Genetic Tests for Pancreatic Cancer

Genetic tests related to Pancreatic Cancer:

# Genetic test Affiliating Genes
1 Carcinoma of Pancreas 29 KRAS SMAD4 STK11 TP53
2 Familial Pancreatic Carcinoma 29
3 Neoplasm of the Pancreas 29

Anatomical Context for Pancreatic Cancer

MalaCards organs/tissues related to Pancreatic Cancer:

41
Pancreas, Liver, T Cells, Lung, Testes, Breast, Lymph Node

The Foundational Model of Anatomy Ontology organs/tissues related to Pancreatic Cancer:

19
Pancreas
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pancreatic Cancer:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Pancreatic Acini Acinar Cells

Publications for Pancreatic Cancer

Articles related to Pancreatic Cancer:

(show top 50) (show all 35016)
# Title Authors PMID Year
1
Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. 9 38 8 71
18762988 2008
2
ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. 9 38 71
11248065 2001
3
DPC4 gene in various tumor types. 9 38 71
8653691 1996
4
MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines. 9 38 8
7845688 1995
5
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. 9 38 8
7726912 1994
6
p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. 9 38 71
8513440 1993
7
Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. 38 8
28099419 2017
8
Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. 38 8
27213290 2016
9
Genomic analyses identify molecular subtypes of pancreatic cancer. 38 8
26909576 2016
10
Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. 38 8
26168401 2015
11
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. 38 8
25356972 2015
12
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. 38 8
26106858 2015
13
Whole genomes redefine the mutational landscape of pancreatic cancer. 38 8
25719666 2015
14
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. 38 8
23535601 2013
15
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. 38 8
23103869 2012
16
CDKN2A is the main susceptibility gene in Italian pancreatic cancer families. 38 8
22368299 2012
17
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. 38 8
21436454 2011
18
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. 38 8
20981101 2010
19
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. 38 8
20981102 2010
20
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. 38 8
20101243 2010
21
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. 38 8
19648918 2009
22
MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. 9 38 88
19714243 2009
23
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. 38 8
19460966 2009
24
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. 38 71
19264984 2009
25
Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. 9 38 88
19407485 2009
26
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. 38 8
18772397 2008
27
The P239S palladin variant does not account for a significant fraction of hereditary or early onset pancreas cancer. 38 71
17415588 2007
28
Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. 38 71
17194196 2006
29
Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma. 38 8
15912495 2005
30
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. 38 8
14520413 2003
31
Progression model for pancreatic cancer. 38 8
10955772 2000
32
Inheritance of pancreatic cancer in pancreatic cancer-prone families. 38 8
10872424 2000
33
Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. 38 71
10362809 1999
34
Characterization of a carboxy-terminal BRCA1 interacting protein. 38 71
9811458 1998
35
Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. 38 8
9091646 1997
36
Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. 38 8
7666917 1995
37
Familial pancreatic adenocarcinoma: association with diabetes and early molecular diagnosis. 38 8
7616537 1995
38
Medical genetic study of eight pancreatic cancer-prone families. 38 8
7874567 1995
39
Detection of point mutations in the Kirsten-ras oncogene provides evidence for the multicentricity of pancreatic carcinoma. 38 71
8439212 1993
40
Familial pancreatic adenocarcinoma in three generations. A case report and a review of the literature. 38 8
3828965 1987
41
Pancreatic cancer in father and son. 38 8
67325 1977
42
Familial carcinoma of the pancreas. 38 8
1269168 1976
43
Efficacy and safety of Kanglaite injection combined with radiochemotherapy in the treatment of advanced pancreatic cancer: A PRISMA-compliant meta-analysis. 38 17
31393364 2019
44
The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. 8
27049944 2016
45
A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. 71
25394175 2015
46
The UPF1 RNA surveillance gene is commonly mutated in pancreatic adenosquamous carcinoma. 8
24859531 2014
47
American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. 71
24493721 2014
48
p53 status determines the role of autophagy in pancreatic tumour development. 8
24305049 2013
49
Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. 71
22683711 2012
50
Keratinocytic epidermal nevi are associated with mosaic RAS mutations. 71
22499344 2012

Variations for Pancreatic Cancer

ClinVar genetic disease variations for Pancreatic Cancer:

6 (show top 50) (show all 150)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 STK11 NM_000455.4(STK11): c.108C> A (p.Tyr36Ter) single nucleotide variant Pathogenic rs137853079 19:1207020-1207020 19:1207021-1207021
2 STK11 NM_000455.4(STK11): c.650del (p.Pro217fs) deletion Pathogenic rs397518442 19:1220632-1220632 19:1220633-1220633
3 STK11 NM_000455.4(STK11): c.936del (p.Lys312fs) deletion Pathogenic rs397518443 19:1222999-1222999 19:1223000-1223000
4 ACVR1B NM_020328.4(ACVR1B): c.1282_1286del (p.Asp428fs) deletion Pathogenic rs387906389 12:52380624-52380628 12:51986840-51986844
5 ACVR1B NM_020328.4(ACVR1B): c.1385-502_1515+24del deletion Pathogenic rs1555162597 12:52385145-52385801 12:51991361-51992017
6 SMAD4 NM_005359.5(SMAD4): c.1072G> T (p.Gly358Ter) single nucleotide variant Pathogenic rs121912576 18:48591909-48591909 18:51065539-51065539
7 SMAD4 NM_005359.5(SMAD4): c.1477G> C (p.Asp493His) single nucleotide variant Pathogenic rs121912578 18:48604655-48604655 18:51078285-51078285
8 SMAD4 NM_005359.5(SMAD4): c.1543A> T (p.Arg515Ter) single nucleotide variant Pathogenic rs121912579 18:48604721-48604721 18:51078351-51078351
9 TP53 NM_000546.5(TP53): c.105G> T (p.Leu35Phe) single nucleotide variant Pathogenic rs121912661 17:7579582-7579582 17:7676264-7676264
10 TP53 NM_000546.5(TP53): c.524G> A (p.Arg175His) single nucleotide variant Pathogenic rs28934578 17:7578406-7578406 17:7675088-7675088
11 BRCA1 NM_007294.3(BRCA1): c.5266dupC (p.Gln1756Profs) duplication Pathogenic rs80357906 17:41209082-41209082 17:43057065-43057065
12 SMAD4 NM_005359.5(SMAD4): c.1236C> G (p.Tyr412Ter) single nucleotide variant Pathogenic rs121912577 18:48593485-48593485 18:51067115-51067115
13 SMAD4 NM_005359.5(SMAD4): c.1498A> G (p.Ile500Val) single nucleotide variant Pathogenic rs281875322 18:48604676-48604676 18:51078306-51078306
14 PALB2 NM_024675.3(PALB2): c.1652dup (p.Tyr551Ter) duplication Pathogenic rs1555461176 16:23646215-23646215 16:23634893-23634894
15 BRCA2 NM_000059.3(BRCA2): c.6405_6409del (p.Asn2135fs) deletion Pathogenic rs80359584 13:32914897-32914901 13:32340760-32340764
16 BRCA2 NM_000059.3(BRCA2): c.4525C> T (p.Gln1509Ter) single nucleotide variant Pathogenic rs80358683 13:32913017-32913017 13:32338880-32338880
17 BRCA2 NM_000059.3(BRCA2): c.6408_6414del (p.Asn2137fs) deletion Pathogenic rs397507851 13:32914900-32914906 13:32340763-32340769
18 PALB2 NM_024675.3(PALB2): c.2167_2168del (p.Met723fs) deletion Pathogenic rs587776416 16:23641307-23641308 16:23629986-23629987
19 SMAD4 NM_005359.5(SMAD4): c.1245_1248delCAGA (p.Asp415Glufs) deletion Pathogenic rs80338965 18:48593494-48593497 18:51067124-51067127
20 SMAD4 NM_005359.5(SMAD4): c.1082G> A (p.Arg361His) single nucleotide variant Pathogenic rs377767347 18:48591919-48591919 18:51065549-51065549
21 KRAS NM_004985.5(KRAS): c.458A> T (p.Asp153Val) single nucleotide variant Pathogenic rs104894360 12:25362838-25362838 12:25209904-25209904
22 KRAS NM_004985.5(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 12:25398284-25398284 12:25245350-25245350
23 KRAS NM_004985.5(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 12:25398284-25398284 12:25245350-25245350
24 TMEM71 ; TSC1 t(8;9)(q24.22;q34.13) Translocation Pathogenic 8:133731583-133731584 :0-0
25 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 17:7577120-7577120 17:7673802-7673802
26 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 17:7577538-7577538 17:7674220-7674220
27 TP53 NM_000546.5(TP53): c.559+1G> A single nucleotide variant Pathogenic/Likely pathogenic rs1131691042 17:7578370-7578370 17:7675052-7675052
28 TP53 NM_000546.5(TP53): c.96+1G> T single nucleotide variant Pathogenic/Likely pathogenic rs1131691003 17:7579699-7579699 17:7676381-7676381
29 NEK8 NM_178170.3(NEK8): c.589G> C (p.Ala197Pro) single nucleotide variant Likely pathogenic rs756231248 17:27062360-27062360 17:28735342-28735342
30 STK33 NM_030906.4(STK33): c.969T> G (p.Phe323Leu) single nucleotide variant Likely pathogenic rs1057520013 11:8457665-8457665 11:8436118-8436118
31 TTK NM_003318.5(TTK): c.2089G> T (p.Asp697Tyr) single nucleotide variant Likely pathogenic rs1057520011 6:80747723-80747723 6:80038006-80038006
32 TP53 NM_000546.5(TP53): c.799C> T (p.Arg267Trp) single nucleotide variant Likely pathogenic rs55832599 17:7577139-7577139 17:7673821-7673821
33 STK11 NM_000455.4(STK11): c.719C> G (p.Ser240Trp) single nucleotide variant Likely pathogenic rs730881976 19:1220701-1220701 19:1220702-1220702
34 STK11 NM_000455.4(STK11): c.582C> G (p.Asp194Glu) single nucleotide variant Likely pathogenic rs786202134 19:1220489-1220489 19:1220490-1220490
35 STK11 NM_000455.4(STK11): c.582C> A (p.Asp194Glu) single nucleotide variant Likely pathogenic rs786202134 19:1220489-1220489 19:1220490-1220490
36 TP53 NM_000546.5(TP53): c.466C> T (p.Arg156Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs563378859 17:7578464-7578464 17:7675146-7675146
37 SMAD4 NM_005359.5(SMAD4): c.677C> T (p.Ala226Val) single nucleotide variant Conflicting interpretations of pathogenicity rs539739051 18:48584504-48584504 18:51058134-51058134
38 STK11 NM_000455.4(STK11): c.632G> A (p.Arg211Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs730881982 19:1220614-1220614 19:1220615-1220615
39 PALLD NM_016081.4(PALLD): c.3094C> T (p.Arg1032Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs548068667 4:169845492-169845492 4:168924341-168924341
40 BRCA2 NM_000059.3(BRCA2): c.353G> A (p.Arg118His) single nucleotide variant Conflicting interpretations of pathogenicity rs80358603 13:32899249-32899249 13:32325112-32325112
41 PALLD NM_016081.4(PALLD): c.2084T> G (p.Leu695Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs139375029 4:169812192-169812192 4:168891041-168891041
42 PALLD NM_016081.4(PALLD): c.539C> T (p.Thr180Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs146387060 4:169433194-169433194 4:168512043-168512043
43 PALLD NM_016081.4(PALLD): c.731A> G (p.Gln244Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs114946738 4:169433386-169433386 4:168512235-168512235
44 PALLD NM_016081.4(PALLD): c.909A> T (p.Arg303Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs138897963 4:169589341-169589341 4:168668190-168668190
45 BRCA2 NM_000059.3(BRCA2): c.6325G> A (p.Val2109Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs79456940 13:32914817-32914817 13:32340680-32340680
46 BRCA2 NM_000059.3(BRCA2): c.10150C> T (p.Arg3384Ter) single nucleotide variant Conflicting interpretations of pathogenicity rs397507568 13:32972800-32972800 13:32398663-32398663
47 BRCA2 NM_000059.3(BRCA2): c.7522G> A (p.Gly2508Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs80358978 13:32930651-32930651 13:32356514-32356514
48 BRCA1 NM_007294.3(BRCA1): c.811G> A (p.Val271Met) single nucleotide variant Conflicting interpretations of pathogenicity rs80357244 17:41246737-41246737 17:43094720-43094720
49 BRCA2 NM_000059.3(BRCA2): c.1568A> G (p.His523Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs80358443 13:32907183-32907183 13:32333046-32333046
50 BRCA1 NM_007294.3(BRCA1): c.3327_3329del (p.Lys1110del) deletion Conflicting interpretations of pathogenicity rs80357575 17:41244219-41244221 17:43092202-43092204

Cosmic variations for Pancreatic Cancer:

9 (show top 50) (show all 80)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6920561 TRAF7 pancreas,NS,carcinoma,acinar carcinoma c.1187A>G p.Q396R 16:2173972-2173972 63
2 COSM6955726 TRAF2 pancreas,NS,carcinoma,acinar carcinoma c.876G>T p.E292D 9:136920431-136920431 63
3 COSM6977589 SPOP pancreas,NS,carcinoma,acinar carcinoma c.838-1G>A p.? 17:49602008-49602008 63
4 COSM6977592 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 63
5 COSM6784678 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1597C>A p.L533I 18:51078405-51078405 63
6 COSM4754647 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1600C>T p.Q534* 18:51078408-51078408 63
7 COSM14249 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1156G>C p.G386R 18:51067035-51067035 63
8 COSM6955723 SETD2 pancreas,NS,carcinoma,acinar carcinoma c.2816C>A p.S939* 3:47120311-47120311 63
9 COSM6977590 RPTOR pancreas,NS,carcinoma,acinar carcinoma c.485G>A p.G162E 17:80707977-80707977 63
10 COSM6977587 ROS1 pancreas,NS,carcinoma,acinar carcinoma c.5756C>A p.A1919D 6:117321280-117321280 63
11 COSM6934092 RARA pancreas,NS,carcinoma,acinar carcinoma c.995T>A p.I332N 17:40354489-40354489 63
12 COSM6974631 RARA pancreas,NS,carcinoma,acinar carcinoma c.1285G>T p.G429C 17:40356122-40356122 63
13 COSM6941250 PTPRD pancreas,NS,carcinoma,acinar carcinoma c.5594G>C p.R1865T 9:8319907-8319907 63
14 COSM5327 PTEN pancreas,NS,carcinoma,acinar carcinoma c.740T>A p.L247* 10:87957958-87957958 63
15 COSM6955728 PTEN pancreas,NS,carcinoma,acinar carcinoma c.686C>A p.S229* 10:87957904-87957904 63
16 COSM6927948 PLCG2 pancreas,NS,carcinoma,acinar carcinoma c.3622G>A p.E1208K 16:81956746-81956746 63
17 COSM6955738 PLCG2 pancreas,NS,carcinoma,acinar carcinoma c.2462C>A p.S821Y 16:81927126-81927126 63
18 COSM763 PIK3CA pancreas,NS,carcinoma,acinar carcinoma c.1633G>A p.E545K 3:179218303-179218303 63
19 COSM4186192 PBRM1 pancreas,NS,carcinoma,acinar carcinoma c.2884G>T p.D962Y 3:52589151-52589151 63
20 COSM6955743 PAK5 pancreas,NS,carcinoma,acinar carcinoma c.1657C>A p.L553M 20:9557694-9557694 63
21 COSM6961498 NKX2-1 pancreas,NS,carcinoma,acinar carcinoma c.578A>T p.H193L 14:36517816-36517816 63
22 COSM6976390 NFE2L2 pancreas,NS,carcinoma,acinar carcinoma c.838G>T p.D280Y 2:177231765-177231765 63
23 COSM6977500 NF1 pancreas,NS,carcinoma,acinar carcinoma c.7786G>T p.V2596F 17:31357007-31357007 63
24 COSM532 KRAS pancreas,NS,carcinoma,acinar carcinoma c.38G>A p.G13D 12:25245347-25245347 63
25 COSM520 KRAS pancreas,NS,carcinoma,acinar carcinoma c.35G>T p.G12V 12:25245350-25245350 63
26 COSM521 KRAS pancreas,NS,carcinoma,acinar carcinoma c.35G>A p.G12D 12:25245350-25245350 63
27 COSM221052 KMT2D pancreas,NS,carcinoma,acinar carcinoma c.9187C>T p.Q3063* 12:49037359-49037359 63
28 COSM6936263 KMT2D pancreas,NS,carcinoma,acinar carcinoma c.10090C>T p.Q3364* 12:49033805-49033805 63
29 COSM6921306 INPP4B pancreas,NS,carcinoma,acinar carcinoma c.292T>G p.F98V 4:142403018-142403018 63
30 COSM6955721 IKBKE pancreas,NS,carcinoma,acinar carcinoma c.1956G>T p.Q652H 1:206493289-206493289 63
31 COSM28747 IDH1 pancreas,NS,carcinoma,acinar carcinoma c.394C>T p.R132C 2:208248389-208248389 63
32 COSM3430388 H3C2 pancreas,NS,carcinoma,acinar carcinoma c.258G>C p.Q86H 6:26031803-26031803 63
33 COSM6934091 GRIN2A pancreas,NS,carcinoma,acinar carcinoma c.527T>A p.I176N 16:9938439-9938439 63
34 COSM27895 GNAS pancreas,NS,carcinoma,acinar carcinoma c.602G>A p.R201H 20:58909366-58909366 63
35 COSM6955729 FGF19 pancreas,NS,carcinoma,acinar carcinoma c.574C>A p.L192M 11:69699339-69699339 63
36 COSM4967292 FAT1 pancreas,NS,carcinoma,acinar carcinoma c.11216C>T p.A3739V 4:186603310-186603310 63
37 COSM6934088 EGFR pancreas,NS,carcinoma,acinar carcinoma c.3541G>C p.A1181P 7:55205525-55205525 63
38 COSM6960278 EED pancreas,NS,carcinoma,acinar carcinoma c.445A>T p.T149S 11:86256405-86256405 63
39 COSM5676 CTNNB1 pancreas,NS,carcinoma,acinar carcinoma c.122C>T p.T41I 3:41224634-41224634 63
40 COSM5667 CTNNB1 pancreas,NS,carcinoma,acinar carcinoma c.134C>T p.S45F 3:41224646-41224646 63
41 COSM5679 CTNNB1 pancreas,NS,carcinoma,acinar carcinoma c.110C>G p.S37C 3:41224622-41224622 63
42 COSM5686 CTNNB1 pancreas,NS,carcinoma,acinar carcinoma c.100G>A p.G34R 3:41224612-41224612 63
43 COSM5689 CTNNB1 pancreas,NS,carcinoma,acinar carcinoma c.134C>G p.S45C 3:41224646-41224646 63
44 COSM6955735 CD276 pancreas,NS,carcinoma,acinar carcinoma c.308G>T p.G103V 15:73702483-73702483 63
45 COSM6955741 AXIN2 pancreas,NS,carcinoma,acinar carcinoma c.1665C>A p.C555* 17:65537371-65537371 63
46 COSM6955736 AXIN1 pancreas,NS,carcinoma,acinar carcinoma c.1210G>T p.E404* 16:304348-304348 63
47 COSM6977595 ATRX pancreas,NS,carcinoma,acinar carcinoma c.5438G>A p.G1813E 23:77618816-77618816 63
48 COSM6955731 ATM pancreas,NS,carcinoma,acinar carcinoma c.6415G>T p.E2139* 11:108320021-108320021 63
49 COSM19021 APC pancreas,NS,carcinoma,acinar carcinoma c.4330C>T p.Q1444* 5:112839924-112839924 63
50 COSM94388 pancreas,NS,carcinoma,acinar carcinoma c.2531G>A p.R844H 20:58909366-58909366 63

Copy number variations for Pancreatic Cancer from CNVD:

7 (show top 50) (show all 15981)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13839 1 100027661 100101597 Gain and loss AGL Pancreatic cancer
2 13849 1 100147561 100201027 Gain and loss SLC35A3 Pancreatic cancer
3 13857 1 100215810 100260948 Gain and loss HIAT1 Pancreatic cancer
4 13861 1 100261125 100310532 Gain and loss SASS6 Pancreatic cancer
5 13862 1 10027309 10175557 Gain and loss UBE4B Pancreatic cancer
6 13871 1 100326522 100355822 Gain and loss LRRC39 Pancreatic cancer
7 13875 1 100372897 100427397 Gain and loss DBT Pancreatic cancer
8 13880 1 100443784 100469348 Gain and loss RTCD1 Pancreatic cancer
9 13887 1 100530068 100697853 Gain and loss CDC14A Pancreatic cancer
10 13901 1 100715714 100719589 Gain and loss GPR88 Pancreatic cancer
11 13916 1 100897318 100916618 Gain and loss VCAM1 Pancreatic cancer
12 13924 1 101049969 101073575 Gain and loss EXTL2 Pancreatic cancer
13 13925 1 101073653 101157013 Gain and loss SLC30A7 Pancreatic cancer
14 13931 1 101167641 101203392 Gain and loss DPH5 Pancreatic cancer
15 13942 1 101414596 101419094 Gain and loss EDG1 Pancreatic cancer
16 13966 1 101980154 102174569 Gain and loss OLFM3 Pancreatic cancer
17 13979 1 10205097 10375920 Gain and loss KIF1B Pancreatic cancer
18 14027 1 103055016 103286073 Gain and loss COL11A1 Pancreatic cancer
19 14059 1 103780424 103834168 Gain and loss RNPC3 Pancreatic cancer
20 14081 1 103871529 103880389 Gain and loss AMY2A Pancreatic cancer
21 14091 1 103910910 103919188 Gain and loss AMY1A Pancreatic cancer
22 14093 1 10393351 10414467 Gain and loss PGD Pancreatic cancer
23 14151 1 10424425 10446476 Gain and loss APITD1 Pancreatic cancer
24 14168 1 10454871 10466879 Gain and loss DFFA Pancreatic cancer
25 14176 1 10469278 10625079 Gain and loss PEX14 Pancreatic cancer
26 14277 1 10641535 10790973 Gain and loss CASZ1 Pancreatic cancer
27 14348 1 107311380 107313956 Gain and loss HRMT1L6 Pancreatic cancer
28 14354 1 107395591 107665249 Gain and loss NTNG1 Pancreatic cancer
29 14396 1 107825832 108219580 Gain and loss VAV3 Pancreatic cancer
30 14412 1 107915304 108309068 Gain or loss VAV3 Pancreas cancer
31 14435 1 108389491 108454940 Gain and loss SLC25A24 Pancreatic cancer
32 14445 1 108477129 108498715 Gain and loss NBPF4 Pancreatic cancer
33 14472 1 108630504 108640564 Gain and loss NBPF5 Pancreatic cancer
34 14486 1 108815093 108889808 Gain and loss FAM102B Pancreatic cancer
35 14495 1 108947005 108956462 Gain and loss PRPF38B Pancreatic cancer
36 14496 1 108977028 108997407 Gain and loss FNDC7 Pancreatic cancer
37 14498 1 109001350 109064190 Gain and loss STXBP3 Pancreatic cancer
38 14509 1 109131869 109185060 Gain and loss GPSM2 Pancreatic cancer
39 14514 1 109184172 109218121 Gain and loss CLCC1 Pancreatic cancer
40 14518 1 109224882 109296777 Gain and loss WDR47 Pancreatic cancer
41 14530 1 109319187 109330611 Gain and loss TAF13 Pancreatic cancer
42 14538 1 109368575 109461639 Gain and loss KIAA1324 Pancreatic cancer
43 14554 1 109468582 109492827 Gain and loss SARS Pancreatic cancer
44 14558 1 109504683 109530414 Gain and loss CELSR2 Pancreatic cancer
45 14588 1 109568465 109652615 Gain and loss SORT1 Pancreatic cancer
46 14603 1 109594163 109619901 Gain or loss CELSR2 Pancreas cancer
47 14615 1 109656520 109681079 Gain and loss PSMA5 Pancreatic cancer
48 14617 1 109721142 109734212 Gain and loss SYPL2 Pancreatic cancer
49 14619 1 109738603 109747396 Gain and loss ATXN7L2 Pancreatic cancer
50 14623 1 109748763 109755097 Gain and loss CYB561D1 Pancreatic cancer

Expression for Pancreatic Cancer

Search GEO for disease gene expression data for Pancreatic Cancer.

Pathways for Pancreatic Cancer

Pathways related to Pancreatic Cancer according to KEGG:

37
# Name Kegg Source Accession
1 Pancreatic cancer hsa05212

GO Terms for Pancreatic Cancer

Cellular components related to Pancreatic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lateral element GO:0000800 8.62 BRCA2 BRCA1

Biological processes related to Pancreatic Cancer according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.97 TP53 STK11 SMAD4 MIR221 MIR21 MIR15A
2 negative regulation of gene expression GO:0010629 9.92 MIR21 MIR17 MIR155 CDKN2B-AS1 ACVR1B
3 positive regulation of gene expression GO:0010628 9.91 TP53 MIR34A MIR21 KRAS CDKN2B-AS1 BRCA1
4 negative regulation of cell growth GO:0030308 9.86 TP53 STK11 SMAD4 ACVR1B
5 DNA recombination GO:0006310 9.85 PALB2 BRCA2 BRCA1
6 negative regulation of angiogenesis GO:0016525 9.85 MIR34A MIR21 MIR15A MIR10A
7 transforming growth factor beta receptor signaling pathway GO:0007179 9.84 SMAD4 MIR21 ACVR1B
8 double-strand break repair via homologous recombination GO:0000724 9.83 PALB2 BRCA2 BRCA1
9 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.82 SMAD4 MIR221 MIR21
10 negative regulation of protein kinase B signaling GO:0051898 9.8 MIR34C MIR34B MIR34A
11 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.78 MIR221 MIR21 MIR17
12 positive regulation of epithelial to mesenchymal transition GO:0010718 9.77 SMAD4 MIR221 MIR21
13 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.75 MIR96 MIR34A MIR15A
14 positive regulation of cell cycle arrest GO:0071158 9.71 TP53 MIR34A BRCA1
15 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.71 MIR483 MIR221 MIR15A MIR155
16 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.69 MIR483 MIR15A MIR155
17 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.68 MIR34A MIR17
18 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.68 MIR21 MIR17
19 positive regulation of histone H3-K4 methylation GO:0051571 9.67 SMAD4 BRCA1
20 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.67 MIR17 MIR155
21 inner cell mass cell proliferation GO:0001833 9.66 PALB2 BRCA2
22 regulation of protein kinase B signaling GO:0051896 9.65 STK11 MIR21
23 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.65 MIR34A MIR21 MIR15A
24 positive regulation of metalloendopeptidase activity GO:1904685 9.64 MIR21 MIR17
25 positive regulation of histone H3-K9 acetylation GO:2000617 9.63 SMAD4 BRCA1
26 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.63 MIR21 MIR17
27 positive regulation of cellular senescence GO:2000774 9.63 MIR34A MIR10A KRAS
28 negative regulation of regulatory T cell differentiation GO:0045590 9.62 MIR21 MIR155
29 positive regulation of connective tissue replacement GO:1905205 9.62 MIR34C MIR34B MIR34A MIR155
30 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.61 MIR221 MIR155
31 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.61 TP53 BRCA2 BRCA1
32 negative regulation of cell adhesion molecule production GO:0060354 9.59 MIR221 MIR155
33 chordate embryonic development GO:0043009 9.58 BRCA2 BRCA1
34 negative regulation of vascular wound healing GO:0061044 9.57 MIR34A MIR155
35 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.56 MIR34C MIR34B MIR17 MIR155
36 negative regulation of sprouting angiogenesis GO:1903671 9.55 MIR34C MIR34B MIR34A MIR221 MIR17
37 miRNA mediated inhibition of translation GO:0035278 9.5 MIR96 MIR483 MIR221 MIR21 MIR17 MIR15A
38 gene silencing by miRNA GO:0035195 9.36 MIR96 MIR483 MIR34C MIR34B MIR34A MIR221
39 cellular response to DNA damage stimulus GO:0006974 10.04 TP53 STK11 PALB2 BRCA2 BRCA1

Molecular functions related to Pancreatic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.28 MIR96 MIR483 MIR34A MIR221 MIR21 MIR17
2 LRR domain binding GO:0030275 8.96 STK11 KRAS

Sources for Pancreatic Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....